IRLAB Therapeutics AB (OSTO:IRLAB A) Cyclically Adjusted FCF per Share: kr-1.54 (As of Mar. 2026)


OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
36 GF Score
Price kr1.37
GF Value kr11.74
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Cyclically Adjusted FCF per Share?

IRLAB Therapeutics AB OSTO:IRLAB A -1.43% 36 Cyclically Adjusted FCF per Share is kr-1.54 as of Mar. 2026. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 36/100 and a GF Value™ of kr11.74 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

IRLAB Therapeutics AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.343. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-1.54 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-08), IRLAB Therapeutics AB's current stock price is kr1.374. IRLAB Therapeutics AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-1.54. IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF of today is .


IRLAB Therapeutics AB  (OSTO:IRLAB A) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


IRLAB Therapeutics AB Cyclically Adjusted FCF per Share Related Terms


IRLAB Therapeutics AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for IRLAB Therapeutics AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB Cyclically Adjusted FCF per Share Chart

IRLAB Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.55

IRLAB Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.56 -1.61 -1.56 -1.55 -1.54

OSTO:IRLAB A vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF falls into.


OSTO:IRLAB A
36GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IRLAB Therapeutics AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IRLAB Therapeutics AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.343/133.5600*133.5600
=-0.343

Current CPI (Mar. 2026) = 133.5600.

IRLAB Therapeutics AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.311 101.019 -0.411
201609 -0.273 101.138 -0.361
201612 -0.395 102.022 -0.517
201703 -0.383 102.022 -0.501
201706 -0.343 102.752 -0.446
201709 -0.277 103.279 -0.358
201712 -0.550 103.793 -0.708
201803 -0.363 103.962 -0.466
201806 -0.545 104.875 -0.694
201809 -0.080 105.679 -0.101
201812 -0.392 105.912 -0.494
201903 -0.399 105.886 -0.503
201906 -0.558 106.742 -0.698
201909 -0.520 107.214 -0.648
201912 -0.622 107.766 -0.771
202003 -0.497 106.563 -0.623
202006 -0.362 107.498 -0.450
202009 -0.570 107.635 -0.707
202012 -0.312 108.296 -0.385
202103 -0.400 108.360 -0.493
202106 -0.425 108.928 -0.521
202109 3.619 110.338 4.381
202112 -0.509 112.486 -0.604
202203 -0.591 114.825 -0.687
202206 -0.798 118.384 -0.900
202209 -0.536 122.296 -0.585
202212 -0.677 126.365 -0.716
202303 -0.744 127.042 -0.782
202306 -0.943 129.407 -0.973
202309 -0.654 130.224 -0.671
202312 -0.603 131.912 -0.611
202403 -0.681 132.205 -0.688
202406 0.002 132.716 0.002
202409 -0.129 132.304 -0.130
202412 -0.426 132.987 -0.428
202503 0.232 132.825 0.233
202506 -0.804 133.699 -0.803
202509 0.065 133.480 0.065
202512 -0.310 133.390 -0.310
202603 -0.343 133.560 -0.343

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-1.54 mean?
IRLAB Therapeutics AB (OSTO:IRLAB A) has a Cyclically Adjusted FCF per Share of kr-1.54 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on IRLAB Therapeutics AB and its competitors.
Is IRLAB Therapeutics AB's Cyclically Adjusted FCF per Share too high?
IRLAB Therapeutics AB's current Cyclically Adjusted FCF per Share is kr-1.54. Overall, IRLAB Therapeutics AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
IRLAB Therapeutics AB's Cyclically Adjusted FCF per Share of kr-1.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on IRLAB Therapeutics AB and its competitors. IRLAB Therapeutics AB's current Cyclically Adjusted FCF per Share is kr-1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.74, compared to a current price of kr1.37 — trading 88.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-1.54. IRLAB Therapeutics AB's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current Cyclically Adjusted FCF per Share is kr-1.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.37 is trading 88.3% below its estimated GF Value™ of kr11.74. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Cyclically Adjusted FCF per Share: kr-1.54
  • GF Value™: kr11.74 vs. price of kr1.37 (88.3% below fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score

Get the complete analysis for OSTO:IRLAB A

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.37
Price
kr11.74
GF Value